Proxy-12-28-2020 - Report - Page 34
Roche
11/30/2011
11/27/2012
11/11/2013
11/11/2014
11/17/2015
11/17/2015
11/15/2016
11/14/2017
11/13/2018
11/12/2019
Class A
Class A
Class A
Class A
Class A
Class B
Class B
Class B
Class B
Class B
4,000
20,500
10,000
10,000
3,333
6,667
10,000
4,121
2,330
—
—
—
—
—
—
—
—
2,060
4,658
6,794
$
$
$
$
$
$
$
$
$
$
41.820
36.410
61.690
74.380
63.040
65.900
71.648
82.310
80.190
85.950
11/30/2021
11/27/2022
11/11/2023
11/11/2024
11/17/2025
11/17/2025
11/15/2026
11/14/2027
11/13/2028
11/12/2029
11/13/2018
11/12/2019
Class B
Class B
1,871 $ 120,249
1,746 $ 112,215
(1) Equity-based compensation awards are generally granted annually in November. The exercise price of a SAR on Class A
shares will be equal to the fair market value of one Class A share as defined in either the 2008 SAR Plan or the 2014 LTI Plan.
The exercise price of a SAR on Class B shares will be equal to the fair market value of one Class B share as defined in either
the 2008 SAR Plan or the 2014 LTI Plan. The SARs expire ten years after the date of grant. Equity-based compensation
awards are not re-priced or granted retroactively.
(2) The amounts in this column are based upon the market price of the Company's Class B shares on October 2, 2020.
30
30